Oncotarget

Research Papers:

Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program

Juanjuan Li, Yue Xia, Qi Wu, Shan Zhu, Chuang Chen, Wen Yang, Wen Wei and Shengrong Sun _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:49370-49379. https://doi.org/10.18632/oncotarget.17217

Metrics: PDF 1222 views  |   HTML 1564 views  |   ?  


Abstract

Juanjuan Li1,*, Yue Xia2,*, Qi Wu1, Shan Zhu1, Chuang Chen1, Wen Yang1, Wen Wei1 and Shengrong Sun1

1Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, P. R. China

2Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Shengrong Sun, email: sun137@sina.com

Keywords: outcomes, inflammatory breast cancer, molecular subtypes, SEER program

Received: January 20, 2017     Accepted: March 24, 2017     Published: April 19, 2017

ABSTRACT

Background: The aim of this study was to evaluate the outcomes of patients with inflammatory breast cancer (IBC), with emphasis on the role of molecular subtypes and radiotherapy.

Methods: A retrospective cohort study to investigate overall survival (OS) and breast cancer-specific mortality (BCSM) in patients with IBC was conducted using data obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010–2013. Cox multivariate regression was used to calculate the adjusted Hazard Ratios (aHR).

Results: 403 patients were eligible for this study. Patients in the group with hormone receptors (HR)+/HER2- subtype had an OS of 79.6% compared with 89.0 % in the group with (HR)+/HER2+ subtype and 76.8% in the HR-/HER2+ group and 62.9% in the triple-negative (TN) group. BCSM was 16.3% for the HR+/HER2- group, 9.8% for the HR+/HER2+ group, 21.7% for the HR-/HER2+ group, and 30.5% for the TN group. For distant metastases, the results showed that there was a high probability of bone metastasis in HR-positive groups, brain and liver metastasis in HER2-positive groups, and lung metastasis in the TN group. Multivariate analysis demonstrated that estrogen receptor and HER2 positivity were associated with better survival and that the TN subtype had a poorer OS and BCSM compared with other subtypes (P<0.05). Furthermore, patients who received radiotherapy were more likely to have improved survival (P< 0.05).

Conclusion: Inflammatory breast cancer appears to alter the prognosis in association with the receptor status and molecular subtypes. Radiotherapy was still considered to be a crucial treatment for patients with IBC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17217